Table 1.

Post-translational protein modifications of CDKN1A.

Post-Translational Modification	Site	Effector	Observed Effect	Reference
Phosphorylation	Thr-55	MELK (mouse)	Induce interaction CDK2/CDK4	[16]
	Thr-57	MAPK1, MAPK14 and MAPK8	Cytoplasmic localisation and degradation	[17,18]
	Thr-80	LKB1	Degradation	[19]
	Thr-145	AKT1, CHEK1, DAPK1, PIM1, PIM2, PKA	Impairs binding to PCNA Enhances protein stability Alters protein localisation	[20,21]
	Ser-31	Unknown	Unknown/identified using mass spectrometry	[22]
	Ser-98	ASK1	Unknown	[23]
	Ser-114	GSK3-beta	Enhances ubiquitination	[24]
	Ser-123	Unknown	Protein stabilisation	[25]
	Ser-130	CDK6, MAPK, MAPK14, MAPK8	Impairs stability	[26,27]
	Ser 137	Unknown		[28]
	Ser-153	DYRK1B, PKCA	Cytoplasmic localisation	[29]
	Ser-160	PKC	Modulates binding to PCNA	[30]
	Ser-146	AKT, CHEK1, DAPK1, LATS2, NUAK1, PKC, PRKCD, STK38	Impairs binding to PCNA Protein stabilisation	[31,32]
	Tyr-151	Unknown	Unknown	[33]
Ubiquitination	Lys-16 Lys-75 Lys-141 Lys-154 Lys-161 Lys-163	Breast cancer cell growth-induced	Protein degradation	[34]
Acetylation	Lys-141 Lys-154 Lys-161 Lys-163	HDAC1, TSA induced, cell growth and carcinogenesis inhibited	Protein stabilisation enhanced following acetylation	[35]
Methylation	Arg-156	PRMT6	Induction of cytoplasmic localisation	[36]